Gram-negative bacillary meningitis. New therapy and changing concepts

Area of Science:

• Infectious Diseases
• Pharmacology
• Microbiology

Background:

• Cerebrospinal fluid (CSF) has limited opsonic and phagocytic activity, necessitating bactericidal antibiotics for meningitis treatment.
• Traditional antibiotics like chloramphenicol and aminoglycosides lack sufficient bactericidal activity against Gram-negative enteric pathogens at achievable CSF concentrations.
• Gram-negative bacillary meningitis (GNBM) presents a therapeutic challenge due to the limited efficacy of standard antibiotic regimens.

Purpose of the Study:

• To evaluate the efficacy of novel beta-lactam antibiotics, moxalactam disodium and cefotaxime sodium, for treating Gram-negative bacillary meningitis (GNBM).
• To assess the bactericidal activity and cerebrospinal fluid (CSF) penetration of moxalactam disodium and cefotaxime sodium against common GNBM pathogens.

Main Methods:

• Review of existing literature and clinical studies on the use of moxalactam disodium and cefotaxime sodium in treating GNBM.
• Analysis of antibiotic concentrations achieved in CSF and their correlation with bactericidal activity against enteric pathogens.

Main Results:

• Moxalactam disodium and cefotaxime sodium exhibit potent bactericidal activity against a majority of enteric pathogens responsible for GNBM.
• These antibiotics achieve significant concentrations in the CSF, with moxalactam disodium reaching 15-35 µg/mL and cefotaxime sodium reaching 2-10 µg/mL.
• Recent clinical studies report an 85% cure rate for GNBM when treated with these new beta-lactam agents.

Conclusions:

• Moxalactam disodium and cefotaxime sodium represent effective therapeutic options for Gram-negative bacillary meningitis (GNBM).
• Their bactericidal properties and favorable CSF penetration address the limitations of previous antibiotic treatments for GNBM.
• These agents offer a promising advancement in managing serious CNS infections caused by Gram-negative bacteria.